Analyst Activity – Liberum Capital Reiterates Buy on Assura PLC (LON:AGR)

Analyst Ratings For Assura PLC (LON:AGR)

Story continues below

Today, Liberum Capital reiterated its Buy rating on Assura PLC (LON:AGR) with a price target of GBX 60.

There are 1 hold rating, 1 buy rating on the stock.

The current consensus rating on Assura PLC (LON:AGR) is Buy (Score: 2.50) with a consensus target price of GBX 57.50 per share, a potential .

Some recent analyst ratings include

  • 2/27/2017-Liberum Capital Reiterated Rating of Buy.
  • 11/22/2016-Peel Hunt Reiterated Rating of Hold.
  • 5/21/2015-Sanlam Securities Reiterated Rating of Buy.


    About Assura PLC (LON:AGR)
    Assura plc is a United Kingdom-based healthcare real estate investment trust (REIT). The Company is a primary care property investor and developer. The Company develops, invests and manages a portfolio of primary care medical centers across the United Kingdom. The Company’s property portfolio includes Alwoodley Medical Centre, Leeds; Fleetwood Health and Wellbeing Centre, Fleetwood; Frome Medical Practice, Frome; Claremont Medical Centre, Surbiton; Elbury Moor Medical Centre; Grey Gable Surgery; Trellech Surgery; Bewdley Medical Centre; Malmesbury Primary Care Centre, Malmesbury, and Urmston Group Practice, Urmston. The Company’s subsidiaries include Abbey Healthcare Group Ltd, Abbey Healthcare Property Investments Ltd, Assura Aspire Ltd, Assura Aspire UK Ltd, Assura HC UK Ltd, Assura Primary Care Properties Ltd and Assura Trellech Ltd.

    Recent Trading Activity for Assura PLC (LON:AGR)
    Shares of Assura PLC closed the previous trading session at 57.95 down -0.10 -0.17% with 976,714 shares trading hands.

    An ad to help with our costs